Legend Biotech Corp. reported a robust performance for Q4 2024, driven by a significant increase in CARVICTI sales. The company achieved net sales of $334 million for CARVICTI, marking a 110% ...

Legend Biotech Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to Legend Biotech Reports ...

Legend Biotech Corp (LEGN) reported its second-quarter earnings for 2025, revealing a significant increase in revenue but a larger-than-expected loss per share. The company’s revenue reached 255.06 ...

Legend Biotech Corp (LEGN) reported its third-quarter earnings for 2025, revealing a mixed performance that fell short of market expectations. The company posted an earnings per share (EPS) of -$0.05, ...

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech Second Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I ...